NO982696D0 - Anvendelse av tricykliske derivater av 1,4-dihydro-1,4-diokso-1H-naftalen, nye oppnÕdde forbindelser og deres applikasjon i terapi - Google Patents

Anvendelse av tricykliske derivater av 1,4-dihydro-1,4-diokso-1H-naftalen, nye oppnÕdde forbindelser og deres applikasjon i terapi

Info

Publication number
NO982696D0
NO982696D0 NO982696A NO982696A NO982696D0 NO 982696 D0 NO982696 D0 NO 982696D0 NO 982696 A NO982696 A NO 982696A NO 982696 A NO982696 A NO 982696A NO 982696 D0 NO982696 D0 NO 982696D0
Authority
NO
Norway
Prior art keywords
dioxo
dihydro
naphthalene
therapy
application
Prior art date
Application number
NO982696A
Other languages
English (en)
Other versions
NO982696L (no
Inventor
Odile Boutherin-Falson
Stuphanie Desquand-Billiald
Anita Favrou
Michel Finet
Olivier Tembo
Jean-Luc Torregrosa
Sylvie Yannic-Arnoult
Marquer Florence Domagala-Le
Original Assignee
Innothera Lab Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Innothera Lab Sa filed Critical Innothera Lab Sa
Publication of NO982696D0 publication Critical patent/NO982696D0/no
Publication of NO982696L publication Critical patent/NO982696L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/24—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings
    • C07C225/26—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings
    • C07C225/30—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones the carbon skeleton containing carbon atoms of quinone rings having amino groups bound to carbon atoms of quinone rings or of condensed ring systems containing quinone rings of condensed quinone ring systems formed by two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C46/00—Preparation of quinones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/24—Quinones containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C50/00—Quinones
    • C07C50/26—Quinones containing groups having oxygen atoms singly bound to carbon atoms
    • C07C50/32—Quinones containing groups having oxygen atoms singly bound to carbon atoms the quinoid structure being part of a condensed ring system having two rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/60—Naphthoxazoles; Hydrogenated naphthoxazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/84—Naphthothiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/12—One of the condensed rings being a six-membered aromatic ring the other ring being at least seven-membered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO982696A 1995-12-12 1998-06-11 Anvendelse av tricykliske derivater av 1,4-dihydro-1,4-diokso-1H-naftalen, nye oppnÕdde forbindelser og deres applikasjon i terapi NO982696L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR9514683A FR2742153B1 (fr) 1995-12-12 1995-12-12 Utilisation de derives tricycliques du 1,4-dihydro-1,4- dioxo-1h-naphtalene, nouveaux composes obtenus et leur application en therapeutique
PCT/FR1996/001973 WO1997021684A1 (fr) 1995-12-12 1996-12-10 Utilisation de derives tricycliques du 1,4-dihydro-1,4-dioxo-1h-naphtalene, nouveaux composes obtenus et leur application en therapeutique

Publications (2)

Publication Number Publication Date
NO982696D0 true NO982696D0 (no) 1998-06-11
NO982696L NO982696L (no) 1998-08-11

Family

ID=9485393

Family Applications (1)

Application Number Title Priority Date Filing Date
NO982696A NO982696L (no) 1995-12-12 1998-06-11 Anvendelse av tricykliske derivater av 1,4-dihydro-1,4-diokso-1H-naftalen, nye oppnÕdde forbindelser og deres applikasjon i terapi

Country Status (26)

Country Link
US (1) US6262095B1 (no)
EP (1) EP0876356B1 (no)
JP (1) JP2000501724A (no)
KR (1) KR19990072080A (no)
AP (1) AP889A (no)
AR (1) AR005054A1 (no)
AT (1) ATE207907T1 (no)
AU (1) AU716199B2 (no)
BR (1) BR9611935A (no)
CA (1) CA2240279A1 (no)
CZ (1) CZ181198A3 (no)
DE (1) DE69616598D1 (no)
EE (1) EE9800174A (no)
FR (1) FR2742153B1 (no)
HU (1) HUP9901247A3 (no)
ID (1) ID16081A (no)
IL (1) IL124558A0 (no)
LT (1) LT4491B (no)
LV (1) LV12188B (no)
NO (1) NO982696L (no)
NZ (1) NZ323967A (no)
OA (1) OA10696A (no)
PL (1) PL327168A1 (no)
RU (1) RU2178791C2 (no)
TR (1) TR199801069T2 (no)
WO (1) WO1997021684A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003999A (en) * 1997-12-19 1999-07-12 Advanced Research And Technology Institute, Inc. Modulators of ryanodine receptors comprising 2-(aryl)-4,7-dioxobenzothiazoles and analogues thereof
AU2002231139B2 (en) * 2000-12-21 2007-03-22 Bristol-Myers Squibb Company Thiazolyl inhibitors of tec family tyrosine kinases
TWI402261B (zh) 2006-06-19 2013-07-21 Takeda Pharmaceutical 三環化合物及其醫藥組成物
WO2007149484A2 (en) 2006-06-20 2007-12-27 Dana-Farber Cancer Institute Inhibitors of usp1 deubiquitinating enzyme complex
WO2011137320A2 (en) 2010-04-30 2011-11-03 Dana-Farber Cancer Institute, Inc. Small molecule inhibitors of usp1 deubiquitinating enzyme activity
US9040713B2 (en) * 2010-09-27 2015-05-26 Emory University Methods of managing blood sugar levels and compositions related thereto
US9725425B1 (en) 2014-02-25 2017-08-08 Dana-Farber Cancer Institute, Inc. Compounds and methods for treating cancer
RU2545091C1 (ru) * 2014-03-18 2015-03-27 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Российской академии медицинских наук (ФГБУ "РОНЦ им. Н.Н. Блохина" РАМН) 1-R-4,9-ДИОКСО-1H-НАФТО[2,3-d][1,2,3]ТРИАЗОЛ-4-ОКСИМ-2-ОКСИДЫ И ИХ ПРОИЗВОДНЫЕ, ОБЛАДАЮЩИЕ ЦИТОТОКСИЧЕСКОЙ АКТИВНОСТЬЮ
US10829427B2 (en) 2015-12-18 2020-11-10 The Board Of Regents Of The University Of Texas System Naphthoquinones, pro-drugs, and methods of use thereof

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3039925A (en) 1957-04-24 1962-06-19 Bayer Ag Compositions for the treatment of tuberculosis
US4746676A (en) 1984-09-12 1988-05-24 Rorer Pharmaceutical Corporation Carboxyalkyl dipeptide compounds
JPH05112533A (ja) * 1991-05-08 1993-05-07 Upjohn Co:The イミダゾベンゾキノン類およびこれを有効成分とする高血圧・鬱血性心不全の予防・治療剤

Also Published As

Publication number Publication date
ATE207907T1 (de) 2001-11-15
BR9611935A (pt) 1999-05-18
DE69616598D1 (de) 2001-12-06
AR005054A1 (es) 1999-04-07
HUP9901247A3 (en) 2000-08-28
CZ181198A3 (cs) 1998-09-16
FR2742153A1 (fr) 1997-06-13
LV12188B (en) 1999-07-20
EP0876356A1 (fr) 1998-11-11
NZ323967A (en) 2000-06-23
OA10696A (fr) 2002-11-26
FR2742153B1 (fr) 1998-02-13
JP2000501724A (ja) 2000-02-15
ID16081A (id) 1997-09-04
IL124558A0 (en) 1998-12-06
AP889A (en) 2000-11-17
US6262095B1 (en) 2001-07-17
NO982696L (no) 1998-08-11
AP9801275A0 (en) 1998-06-30
EE9800174A (et) 1998-12-15
RU2178791C2 (ru) 2002-01-27
PL327168A1 (en) 1998-11-23
WO1997021684A1 (fr) 1997-06-19
AU1101897A (en) 1997-07-03
CA2240279A1 (fr) 1997-06-19
KR19990072080A (ko) 1999-09-27
LV12188A (lv) 1998-12-20
LT4491B (lt) 1999-04-26
HUP9901247A2 (hu) 1999-08-30
LT98085A (en) 1998-11-25
TR199801069T2 (xx) 1998-08-21
EP0876356B1 (fr) 2001-10-31
AU716199B2 (en) 2000-02-24

Similar Documents

Publication Publication Date Title
GB9613003D0 (en) N-oxides of morpholine derivatives and their use as therapeutic agents
AU6132496A (en) Piperidine and morpholine derivatives and their use as therapeutic agents
AU6132596A (en) Piperidine and morpholine derivatives and their use as therapeutic agents
AU7578696A (en) Morpholine derivatives and their use as therapeutic agents
EE9800459A (et) Spiro-piperidiini derivaadid ja nende kasutamine terapeutiliste toimeainetena
NO933690L (no) Nye tiopyranopyrrolderivater og deres fremstilling
DE69231123D1 (de) Konjugaten von Zell-bindender Mittel und Derivaten von CC-1065
NO972972D0 (no) Sammensetninger for behandling av dermatologiske forstyrrelser og metoder for deres anvendelse
NO975711D0 (no) Nye Dolastatinderivater, deres fremstilling og anvendelse
NO943682D0 (no) Imidazol-4-yl-piperidin-derivater, deres fremstilling og terapeutiske anvendelse
NO982696D0 (no) Anvendelse av tricykliske derivater av 1,4-dihydro-1,4-diokso-1H-naftalen, nye oppnÕdde forbindelser og deres applikasjon i terapi
IS4350A (is) Trísýklísk 5,6-díhýdró-9H-pýrazóló[3,4c]-1,2,4-tríazóló[4,3a]pýridín, notkun þeirra og lyfjablanda
NO953673D0 (no) [1,2,4ÅTriazolo[4,3-aÅkinoksalinderivater, deres fremstilling og anvendelse
NO992676D0 (no) 1,4-diazabicyklo[2,2,2]okt-2-ylmetylderivater, deres fremstilling og terapeutiske anvendelse
DK1000063T3 (da) 4-oxo-3,5-dihydro-4H-pyridazin[4,5-b]indol-1-acetamidderivater, fremstilling heraf og terapeutisk anvendelse heraf
AU3268197A (en) Spiro-piperidine derivatives and their use as therapeutic agents
NO984624L (no) Nye furan-diarylmetyliden-derivater, fremgangsmÕte for deres fremstilling og terapeutiske anvendelser derav
NO932129D0 (no) Fremgangsmaate for fremstilling og anvendelse av nye tienotiazinderivater
NO944906L (no) Ny anvendelse av benzo[gÅkinolinderivater
NO982105D0 (no) Nye mellomprodukter og deres anvendelse for fremstilling av N,N'-broslÕtte bisindolylmaleimider
NO934227D0 (no) Pyrrolderivater, fremgangsm}te for deres fremstilling og terapeutiske anvendelse
AU6003394A (en) Novel heterocyclic aminomethyl-4 piperidine derivatives, their preparation and application in therapy
GB9621419D0 (en) 3-3-disubstituted piperidine derivatives and their use as therapeutic agents
DK0869952T3 (da) Derivater af 5-naphthalen-1-yl-1,3-dioxaner, fremstilling og terapeutisk anvendelse heraf
FI952250A (fi) 5,6-dihydro-4H-tieno/3,4-c/pyrrolijohdannaiset, niiden valmistus ja terapeuttinen käyttö

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application